Comparison of paroxetine and agomelatine in depressed type 2 diabetes mellitus patients: a double-blind, randomized, clinical trial

Abstract

BackgroundComorbid depression/anxiety in type 2 diabetes mellitus (DM) patients is highly prevalent, affecting both diabetes control and quality of life. However, the best treating method for depression/anxiety in type 2 DM patients is still unclear. This study was conducted to compare the efficacy of paroxetine and agomelatine on depression/anxiety and metabolic control of type 2 DM patients.MethodsA total of 116 depressed, type 2 DM patients were recruited for 12 weeks treatment. Patients were randomly assigned to receive either paroxetine or agomelatine. Hamilton Depression Rating Scale and Hamilton Anxiety Rating Scale were used to assess depression and anxiety, respectively. Hemoglobin A1c, fasting plasma glucose, and body mass index were assessed at baseline and at the end of the trial.ResultsAt the end of the trial, there were 34 (60.7%) responders and 22 (39.3%) remissions in paroxetine group; and 38 (63.3%) responders and 26 (43.3%) remissions in agomelatine group. Compared to paroxetine group, lower depression scores were observed in agomelatine group. Fasting plasma glucose and body mass index were not significantly different after 12 weeks treatment between the two groups, but agomelatine group had a significantly lower final hemoglobin A1c level compared to paroxetine group. The two antidepressants had comparable acceptability.ConclusionThese results showed that compared to paroxetine, agomelatine might have some advantages in treating symptoms of depression/anxiety and glycemic control in depressed type 2 DM patients. The clinical applicability of agomelatine shows greater promise and should be explored further. Limited by the relatively small samples, future studies are needed to verify and support our findings.

Agomelatine versus paroxetine in treating depressive and anxiety symptoms in patients with chronic kidney disease

“…Recently, a randomized trial reported that agomelatine had some advantages over paroxetine in treating depressive and anxiety symptoms in patients with type 2 diabetes mellitus. 14 Considering the high prevalence of CKD in diabetes patients, 15 we hypothesize that agomelatine could be more effective than paroxetine in treating depressive and anxiety symptoms in CKD patients. Therefore, we conducted this randomized trial to validate this assumption.…”

Agomelatine versus fluoxetine in glycemic control and treating depressive and anxiety symptoms in type 2 diabetes mellitus subjects: a single-blind randomized controlled trial

“…This study was conducted between January 2015 and June 2017 in Chongqing Public Health Medical Center. T2DM subjects meeting the following criteria were recruited by two experienced clinicians: 1) a value of hemoglobin A1c (HbA1c) >7.0%; 2) a 17-item Hamilton Depression Rating Scale (HDRS-17) score ≧17 and Hamilton Anxiety Rating Scale (HARS) score >7; 19 , 20 3) 18–80 years of age; 4) in order to exclude T2DM subjects with cognitive impairment, the Mini Mental State Examination score of each subject should be more than 24; and 5) without active suicidal ideation, a history of any other psychiatric disorders, and serious mental illness or physical health problems. Meanwhile, T2DM subjects were excluded if they previously or currently received psychoactive medications.…”

Combined application of tenuigenin and β-asarone improved the efficacy of memantine in treating moderate-to-severe Alzheimer’s disease

“…For the purpose of covarying out the effect of initial values, the analysis of covariance (ANCOVA) was used to examine the effect of the two intervention methods on the MMSE, ADL, and CDR scores at the last assessment. 24 Also, subgroup analysis was conducted according to the severity of dementia, age, and sex. All tests were two-sided, and p <0.05 was considered significant.…”